Showcases Stock ranks Forex

Biogen Inc (BIIB)
217.56  -0.64 (-0.29%) 08-08 16:00
Open: 216.79 Pre. Close: 218.2
High: 222.21 Low: 215.38
Volume: 896,371 Market Cap: 31,571M
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 222.337 - 223.472 223.472 - 224.343
Low: 212.759 - 213.941 213.941 - 214.848
Close: 215.689 - 217.672 217.672 - 219.192
Stock Technical Analysis
Target: Six months: 259.54
One year: 303.14
Support: Support1: 211.07
Support2: 204.18
Resistance: Resistance1: 222.21
Resistance2: 259.54
Pivot: 212.92
Moving Averages: MA(5): 215.16
MA(20): 213.47
MA(100): 207.61
MA(250): 236.76
MACD: MACD(12,26): 1.64
Signal(12,26,9): 1.34
%K %D: %K(14,3): 74.94
%D(3): 64.49
RSI: RSI(14): 56.43
52-Week: High: 351.86
Low: 187.16
Change(%): -36.7
Average Vol(K): 3-Month: 1045
10-Days: 914
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ BIIB ] has closed below upper band by 22.4%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Thu, 04 Aug 2022
Biogen Inc. (NASDAQ:BIIB) Short Interest Down 17.1% in July - MarketBeat

Wed, 03 Aug 2022
Victory Capital Management Inc. Purchases 25556 Shares of Biogen Inc. (NASDAQ:BIIB) - Defense World

Wed, 27 Jul 2022
Biogen (NASDAQ:BIIB) Stock Rating Upgraded by - MarketBeat

Tue, 26 Jul 2022
ALS Drug From Biogen Could Become First to Target Genetic Cause of Disease - Bloomberg

Tue, 26 Jul 2022
Biogen Inc. (NASDAQ:BIIB) Holdings Raised by Mutual of America Capital Management LLC - Defense World

Sat, 23 Jul 2022
Biogen Inc. to Post Q3 2022 Earnings of $4.11 Per Share, Oppenheimer Forecasts (NASDAQ:BIIB) - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 145.11
Shares Float (M) 144.68
% Held by Insiders 0.64
% Held by Institutions 87.13
Shares Short (K) 2090
Shares Short Prior Month (K) 2660
Stock Financials
EPS 14.540
Book Value (p.s.) 81.770
Profit Margin 19.36
Operating Margin 27.78
Return on Assets (ttm) 7.4
Return on Equity (ttm) 13.6
Qtrly Rev. Growth -6.7
Gross Profit (p.s.) 61.126
Sales Per Share 73.255
EBITDA (p.s.) 24.120
Qtrly Earnings Growth 142.10
Operating Cash Flow (M) 2540.00
Levered Free Cash Flow (M) 2100.00
Stock Valuation
PE Ratio 14.96
PEG Ratio -1.89
Price to Book value 2.66
Price to Sales 2.97
Price to Cash Flow 12.43
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android